{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:34:32Z","timestamp":1768678472360,"version":"3.49.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2022.980956","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T08:17:40Z","timestamp":1660810660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Editorial: Pandemic influenza vaccine approaches: Current status and future directions"],"prefix":"10.3389","volume":"13","author":[{"given":"Michael","family":"Schotsaert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca Jane","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey P.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41467-022-29402-5","article-title":"Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination","volume":"13","author":"Dhanasekaran","year":"2022","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6937a6","article-title":"Decreased influenza activity during the COVID-19 pandemic - united states, Australia, Chile, and south Africa, 2020","volume":"37","author":"Olsen","year":"2020","journal-title":"Journal title MMWR Morb Mortal Wkly Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"21267857","DOI":"10.1101\/2021.12.15.21267857","article-title":"Antigenic and virological properties of an H3N2 variant that will likely dominate the 2021-2022 northern hemisphere influenza season","author":"Bolton","year":"2021"},{"key":"B4","unstructured":"BragstadK\n          Influenza virological and epidemiological season report prepared for the WHO consultation on the composition of influenza virus vaccines for the northern hemisphere 2022\/2023"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: The strategic plan for the national institute of allergy and infectious diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00024-X","article-title":"Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial","volume":"7","author":"Folschweiller","year":"2022","journal-title":"Lancet Infect Dis S1473-3099(22)00024-X"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30393-7","article-title":"Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial","volume":"1","author":"Bernstein","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198307073090103","article-title":"Cytotoxic T-cell immunity to influenza","volume":"309","author":"McMichael","year":"1983","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz639","article-title":"Pre-existing anti-neuraminidase antibodies are associated with shortened duration of influenza a (H1N1)pdm virus shedding and illness in naturally infected adults","volume":"11","author":"Maier","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/13484","article-title":"A universal influenza a vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.007","article-title":"M2e-based universal influenza a vaccine","volume":"27","author":"Fiers","year":"2009","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.980956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T08:17:42Z","timestamp":1660810662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.980956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2022.980956"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.980956","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"article-number":"980956"}}